Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,153
archived clinical trials in
Gout

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Willoughby Hills, OH
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Willoughby Hills, OH
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Tulsa, OK
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Portland, OR
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Altoona, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Altoona, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Duncansville, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Harleysville, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Harleysville, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Lansdale, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Lansdale, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
McMurray, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
McMurray, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Media, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Media, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Uniontown, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Uniontown, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Wyomissing, PA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Charleston, SC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Columbia, SC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Greer, SC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Mount Pleasant, SC
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Rapid City, SD
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Bristol, TN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Collierville, TN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Collierville, TN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Jackson, TN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Memphis, TN
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Arlington, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Austin, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Bellaire, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Bellaire, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Carrollton, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Corpus Christi, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Humble, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Humble, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Plano, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Sugar Land, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
The Woodlands, TX
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Bountiful, UT
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Bountiful, UT
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Salt Lake City City, UT
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Salt Lake City City, UT
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
West Jordan, UT
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Alexandria, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Arlington, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Arlington, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Burke, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Burke, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Charlottesville, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Danville, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Danville, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Midlothian, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Midlothian, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Newport News, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Norfolk, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Richmond, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Sterling, VA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Sterling, VA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Spokane, WA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Clarksburg, WV
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials